These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 11122720)

  • 1. Does differing metabolism by cytochrome p450 have clinical importance?
    Davidson MH
    Curr Atheroscler Rep; 2000 Jan; 2(1):14-9. PubMed ID: 11122720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Metabolic interactions with statins].
    Molden E; Asberg A
    Tidsskr Nor Laegeforen; 2001 Jan; 121(2):189-93. PubMed ID: 11475198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical pharmacokinetics of fibric acid derivatives (fibrates).
    Miller DB; Spence JD
    Clin Pharmacokinet; 1998 Feb; 34(2):155-62. PubMed ID: 9515185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of human cytochrome P-450 3A4-catalyzed meloxicam 5'-methylhydroxylation by quinidine and hydroquinidine in vitro.
    Ludwig E; Schmid J; Beschke K; Ebner T
    J Pharmacol Exp Ther; 1999 Jul; 290(1):1-8. PubMed ID: 10381752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytochrome P450-mediated cardiovascular drug interactions.
    Scheen AJ
    Expert Opin Drug Metab Toxicol; 2011 Sep; 7(9):1065-82. PubMed ID: 21810031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rhabdomyolysis after concomitant use of cyclosporine, simvastatin, gemfibrozil, and itraconazole.
    Maxa JL; Melton LB; Ogu CC; Sills MN; Limanni A
    Ann Pharmacother; 2002 May; 36(5):820-3. PubMed ID: 11978159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are cytochrome P450 3A enzymes in the small intestine responsible for different cyclosporine metabolite patterns in stable male and female renal allograft recipients after co-administration of diltiazem?
    Christians U; Bleck JS; Lampen A; Bader A; Thiesemann C; Kliem V; Repp H; Westhoff-Bleck M; Manns M; Sewing KF
    Transplant Proc; 1996 Aug; 28(4):2159-61. PubMed ID: 8769186
    [No Abstract]   [Full Text] [Related]  

  • 8. Metabolism of sirolimus in the presence or absence of cyclosporine by genotyped human liver microsomes and recombinant cytochromes P450 3A4 and 3A5.
    Picard N; Djebli N; Sauvage FL; Marquet P
    Drug Metab Dispos; 2007 Mar; 35(3):350-5. PubMed ID: 17151193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-drug interactions: effect of quinidine on nifedipine binding to human cytochrome P450 3A4.
    Koley AP; Robinson RC; Markowitz A; Friedman FK
    Biochem Pharmacol; 1997 Feb; 53(4):455-60. PubMed ID: 9105395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans.
    Wilkinson GR
    J Pharmacokinet Biopharm; 1996 Oct; 24(5):475-90. PubMed ID: 9131486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors.
    Williams D; Feely J
    Clin Pharmacokinet; 2002; 41(5):343-70. PubMed ID: 12036392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pantoprazole and cyclosporine or tacrolimus.
    Schwrer H; Lorf T; Ringe B; Ramadori G
    Aliment Pharmacol Ther; 2001 Apr; 15(4):561-2. PubMed ID: 11284790
    [No Abstract]   [Full Text] [Related]  

  • 13. Interactions between cyclosporin and lipid-lowering drugs: implications for organ transplant recipients.
    Asberg A
    Drugs; 2003; 63(4):367-78. PubMed ID: 12558459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug-grapefruit juice interactions.
    Kane GC; Lipsky JJ
    Mayo Clin Proc; 2000 Sep; 75(9):933-42. PubMed ID: 10994829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy.
    Rätz Bravo AE; Tchambaz L; Krähenbühl-Melcher A; Hess L; Schlienger RG; Krähenbühl S
    Drug Saf; 2005; 28(3):263-75. PubMed ID: 15733030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism-based inactivation of cytochrome P-450-3A4 by mifepristone (RU486).
    He K; Woolf TF; Hollenberg PF
    J Pharmacol Exp Ther; 1999 Feb; 288(2):791-7. PubMed ID: 9918590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolism of fibric acid derivatives.
    Spence JD
    Clin Pharmacokinet; 1998 May; 34(5):419-20. PubMed ID: 9592623
    [No Abstract]   [Full Text] [Related]  

  • 18. CYP3A-like cytochrome P450-mediated metabolism and polarized efflux of cyclosporin A in Caco-2 cells.
    Gan LS; Moseley MA; Khosla B; Augustijns PF; Bradshaw TP; Hendren RW; Thakker DR
    Drug Metab Dispos; 1996 Mar; 24(3):344-9. PubMed ID: 8820426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug-drug interactions in an era of multiple anticoagulants: a focus on clinically relevant drug interactions.
    Vazquez SR
    Blood; 2018 Nov; 132(21):2230-2239. PubMed ID: 30463993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclosporin A-induced free radical generation is not mediated by cytochrome P-450.
    Krauskopf A; Buetler TM; Nguyen NS; Macé K; Ruegg UT
    Br J Pharmacol; 2002 Feb; 135(4):977-86. PubMed ID: 11861326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.